Telomerase catalytic subunit (hTERT) exerts important cellular functions including telomere homeostasis, genetic stability, cell survival and perhaps differentiation. However, the nature of external or internal signals, which regulate hTERT expression in tissues, remains poorly understood. Thus, whereas it has been described that hTERT gene is regulated along the differentiation of primitive myeloid progenitors, the effect of specific cytokines on telomerase expression in each myeloid lineage is currently unknown. Based on these considerations, we have investigated hTERT expression in erythroid cells treated with erythropoietin (EPO) and transforming growth factor b (TGFb), as putative positive and negative regulators, respectively. We describe here that EPO activates hTERT gene transcription in in vitro-expanded primary erythroid precursors as well as in UT7 erythroleukemia cells. In UT7 cells, this study shows also that EPO acts through a JAK2/STAT5/c-myc axis. In contrast, TGFb blocks EPO signaling downstream of c-myc induction through a Smad3-dependent mechanism. Finally, hTERT appears to be efficiently regulated by EPO and TGFb in an opposite way in erythropoietic cells, arguing for a role of telomerase in red blood cell production.
Introduction
Telomerase is a ribonucleoprotein DNA polymerase that elongates the telomeres of chromosomes to compensate their losses during cell division and allow cells to bypass replicative senescence. 1 It is composed of a catalytic protein subunit, telomerase reverse transcriptase (hTERT) and an RNA template (hTR). Previous studies have documented that hTERT represents the rate-limiting state in telomerase activity. 2 This enzyme is regulated by transcriptional and post-transcriptional mechanisms among which hTERT gene regulation is the major contributor. Based on the important cellular functions newly attributed to telomerase, including cell proliferation, genetic stability, DNA repair and negative regulation of apoptosis, the characterization of hTERT transcriptional control emerges as a major field of investigation in cell biology. However, the knowledge about internal or external signals, including growth factors, involved in hTERT gene regulation is still very limited.
As far as hematopoietic cells are concerned, previous studies have indicated that primary human primitive hematopoietic cells display low telomerase activity. However, at least in vitro, enzyme activity increases upon stimulation with appropriate mixture of cytokines in parallel with cell expansion to reach a maximum after one week, then, progressively declines in parallel with differentiation. 3 These observations suggest a function for hematopoietic growth factors (HGF) in hTERT gene regulation. However, the specific role of each HGF on hTERT gene regulation has not been precisely investigated. For example, at the best of our knowledge, the regulation of hTERT in erythroid cells has never been reported.
In this study, we investigated whether erythropoietin (EPO) and transforming growth factor (TGF)b, one of the major positive and negative regulators of erythropoiesis, respectively, may influence hTERT gene transcription and, if this is the case, the molecular mechanism by which they operate.
Materials and methods

Cell culture and treatment
The human leukemic cell line UT7 was grown in a-MEM supplemented with 10% heat-inactivated fetal calf serum (FCS) (Invitrogen Corporation, Cergy Pontoise, France) and recombinant human 1 U/ml EPO. Before each experiment, cells were deprived overnight in a-MEM containing 10% of a mixture of BSA, insulin and transferrin (BIT9500, StemCell Technologies, Grenoble, France), and stimulated with 10 U/ml EPO. For inhibition of signaling pathways, cells were preincubated with PD98059, Wortmannin or AG490 (Calbiochem, VWR International, France). Human recombinant TGFb (R&D Systems, Oxon, UK) was used at 10 ng/ml in coincubation with EPO.
Quantitative RT-PCR (RQ-PCR)
Total RNA were isolated by using Trizol Reagent (Invitrogen, Cergy Pontoise, France). To quantify hTERT transcripts, we used the LightCycler TeloTAGGGhTERT quantification kit (Roche Diagnostics, Mannheim, Germany), as previously described. 4 To quantify c-myc transcripts, we used the following primers: c-myc forward, 5 0 -CACGTCTCCACACATGAG-3 0 , c-myc reverse, 5 0 -TCTTGGCAGCAGGATAGTCCTT-3 0 , Abelson (Abl, used as a housekeeping gene) forward 5 0 -GGAGATAACACTCTAAGCA TAACTAAAGGT-3 0 , and Abl reverse, 5 0 -ATGTAGTTGCTTGG GACCCA-3 0 . RT-PCR was performed using the Quantitect SYBRgreen RT-PCR Kit (Qiagen, Courtaboeuf, France), according to the manufacturer's instructions. Results were expressed as the ratio between hTERT and PBGD transcripts, or c-myc and Abl transcripts, normalized to untreated cells, as previously described. 4 
Telomerase activity
Quantitative determination of telomerase activity was performed using the telomeric repeat amplification protocol (TRAP) with teloTAGGG telomerase PCR ELISA PLUS kit (Roche Diagnostics, Mannheim, Germany), as previously described. 4 The relative telomerase activity (RTA) was determined as absorbance of the sample compared to absorbance of the control template.
Plasmids
Mig-R-DN-hTERT plasmid was obtained by inserting a mutantdominant negative of hTERT 5 in the Murine Stem Cell Virus retroviral vector Mig-R1 containing encephalomyocarditis virus (ECMV) internal ribosomal entry site (IRES) and green fluorescent protein (e-GFP), as previously described. 6 
Retroviral infection
HEK293T cells were cotransfected with vesicular stomatitis virus envelope-expression plasmid (pMDG), encapsidation plasmid pMDgag/pol (kindly provided by Dr Couderc) and either Mig-R or Mig-R-DN-hTERT. UT7 cells were infected with viral supernatants in the presence of 4 mg Polybrene/ml, and infected cells were sorted 3 days later by flow cytometry according to GFP fluorescence.
Percentage of apoptotic cells
Cells starved in EPO or treated by H 2 O 2 or cisplatin were dropped into cytospins and centrifuged at 800 g 5 min. The slides were stained by the May-Grü nwald-Giemsa (MGG) and screened for apoptotic cells based on their morphological aspects.
Western blot
For western blot analysis, the following primary antibodies were used: anti-ERK, anti-c-myc, anti-actin (Santa Cruz, Le Perray en Yvelines, France), anti-phospho-MAPK, anti-phospho-STAT5, anti-STAT5, anti-phospho-AKT (Ser473), anti-AKT, anti-phospho-Smad3 (Cell Signaling, Ozyme, Saint Quentin en Yvelines, France), anti-Smad3 (Zymed laboratories Inc, Invitrogen, Cergy Pontoise, France) and horseradish peroxidase labeled anti-mouse and anti-rabbit secondary antibodies. Proteins were visualized using the ECL detection system (Pierce, Rockford, IL, USA).
Electrophoretic mobility shift assay
Nuclear proteins were extracted using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce, Rockford, IL, USA). An oligonucleotide probe containing the c-myc binding motif (5 0 -GCGCTTCCCACGTGGCGGAGGG-3 0 ) or specific protein 1 (Sp1) binding motif (5 0 -TCCTTTCCGCGGCCCCGCCCTCTCC TCGCGGCGCGA-3 0 ) of the hTERT promoter was prepared and end-labeled with biotin by TibMolbiol (Berlin, Germany). Detection of c-myc and Sp1 oligonucleotide complex was performed as previously described. 7 Small interfering RNA UT7 cells were transfected with c-myc siRNA, scramble negative control (Ambion Inc., Huntingdon, UK) or Smad3 siRNA (Smad3 Validated Stealth RNAi DuoPack, Invitrogen, Cergy Pontoise, France) using the Amaxa nucleofection technology (Amaxa, Koeln, Germany).
Amplification and purification of normal human erythroid progenitors
Normal bone marrow CD34 þ hematopoietic progenitor cells (HPC) were obtained from discarded fragments of five hematological healthy patients undergoing hip surgery after informed consent. Isolation of HPCs was performed by positive selection of CD34-expressing cells as previously described. 8 Human progenitors (5 Â 10 5 cells/ml) were cultured for 7 days in serumfree Iscove Dulbecco MEM (DMEM) containing 15% BIT9500 supplemented with 25 ng/ml stem cell factor, 10 ng/ml interleukin 3, 10 ng/ml interleukin 6 (R&D Systems, Oxon, UK). At day 7, CD36 þ cells (erythroid progenitors) were obtained by positive selection on CD36 þ immunomagnetic beads, as previously reported, 9 cultured in DMEM with 15% BIT9500 for 4 h (without any cytokines) and then stimulated with EPO (10 U/ml) for 6 h, with or without AG490, PD98059, Wortmannin and TGFb.
Statistics
Results are expressed as mean values7s.d. Statistical analysis of the data was performed by the Student's t-test. Differences were considered as significant for P values o0.05.
Results
EPO regulates hTERT gene and telomerase activity in UT7 cells
To analyze hTERT regulation by EPO, UT7 cells were EPO-and FCS-deprived overnight, then stimulated with 10 U/ml EPO for 48 h. hTERT transcripts and protein activity were measured. As shown in Figure 1 , deprivation resulted in a decrease in hTERT transcripts ( Figure 1a ) but not in reduced telomerase activity ( Figure 1b ). This result is consistent with half-life of the protein, hTERT regulation in human erythroid cells N Prade-Houdellier et al which is longer than 16 h. Moreover, when cells were restimulated, EPO activation resulted in a time-dependent and sustained increase in hTERT transcription and telomerase enzymatic activity. Interestingly, EPO stimulated hTERT gene expression as early as 6 h (Figure 1a ), whereas cell proliferation was detected not before 24 h stimulation as revealed by BrdU/PI double-staining procedure (data not shown).
These results showed that EPO regulated hTERT gene expression and enzyme activity in UT7 cells.
Influence of telomerase activity on EPO-mediated cell proliferation and survival
In further experiments, we evaluate the possible function of EPO-mediated hTERT regulation on cell proliferation and survival. To investigate this hypothesis, UT7 cells have been stably transduced by retroviral infection with hTERT dominantnegative mutant (DN-hTERT). After only two passages, these cells were EPO-deprived overnight and re-stimulated by 10 U/ml EPO for 15 days. In these experiments, we found that EPO stimulated telomerase activity in UT7-Mig-R control cells, but not in UT7-DN-hTERT cells (Figure 2a ). However, EPOmediated cell growth stimulation was found to be similar in hTERT-deficient UT7 cells, compared to control cells over 15 days (Figure 2b ). As previously described, 6 after 4 weeks, UT7-DN-hTERT cell proliferation declined, then cells died (data not shown). These results showed that EPO-mediated hTERT regulation was not implicated in the proliferative response to EPO. In further experiments, we found that the abrogation of telomerase activity had no impact on apoptosis induced by various stress conditions including starvation, oxidative stress or treatment with genotoxic agent (Figure 2c ).
These experiments showed that, whereas telomerase is required for long-term proliferation, EPO-mediated hTERT expression did not serve for early proliferative response to EPO.
c-myc mediates EPO-dependent hTERT gene regulation in UT7 cells
In further experiments, we investigated the mechanism by which EPO could regulate hTERT gene. Previous studies have established that the transcription factor c-myc is a major contributor of hTERT gene regulation. 10 Other independent studies have shown that EPO stimulates c-myc gene transcription. 11 Therefore, it was tempting to speculate that c-myc mediates EPO-dependent hTERT regulation in UT7 cells. For this reason, we performed EMSA, using an oligonucleotide probe containing the c-myc binding motif of hTERT gene promoter. As shown in Figure 3a , DNA-binding activity of c-myc to this specific motif was greatly enhanced by EPO within 2 and 6 h of stimulation. The specificity of c-myc binding to this region was confirmed by the complete competition of the c-myc DNA complex with the presence of non-labeled oligonucleotide. Moreover, the presence of c-myc in the protein DNA complex was confirmed with the supershift of the DNA/protein band (data not shown). As a control, the DNA-binding activity of Sp1, another hTERT gene regulator, remained stable upon EPO stimulation (data not shown). Additional experiments showed that, in UT7 cells, EPO enhanced c-myc transcription (Figure 3b ) and protein expression (Figure 3c) .
To confirm the specific role of c-myc in EPO-dependent hTERT gene regulation, we evaluated the influence of c-myc depletion on EPO-dependent hTERT regulation. For this reason, UT7 cells were transfected with siRNA targeted to c-myc. In these conditions, c-myc was efficiently depleted (Figure 3d ) and 
JAK2-STAT5 mediates EPO-dependent hTERT gene regulation in UT7 cells
The EPO receptor (EPO-R) signals through different pathways including PI3K/AKT, MAPK and JAK2/STAT5. 12 We investigated which pathway could be involved in EPO-dependent c-myc and hTERT gene regulation. For this reason, UT7 cells were starved from EPO and FCS, then, preincubated with a PI3 K inhibitor wortmannin (50 nM for 30 min), a MAPKK inhibitor PD98059 (50 mM for 1 h) or a JAK2 inhibitor AG490 (100 mM for 16 h), and finally stimulated with EPO within 6 h. As controls, we checked that conditions of use of each inhibitor were efficient to inhibit AKT, ERK and STAT5 activation by phosphorylation respectively (Figure 4a) . Our experiments showed that AG490, but not wortmannin or PD98059, inhibited the increase in c-myc protein and gene expression (Figure 4b and data not shown) as well as c-myc DNA-binding activity on hTERT promoter (Figure 4c ) in EPO-stimulated cells. Moreover, AG490 blocked EPO-induced hTERT gene transcription, suggesting that JAK2/ STAT5 is involved in EPO-dependent hTERT regulation (Figure 4d) .
These results suggested that the JAK2-STAT5 pathway was specifically involved in EPO-mediated hTERT gene regulation via c-myc.
Effect of TGFb on hTERT regulation by EPO in UT7 cells
TGFb is an inhibitory growth factor that retains proliferation and promotes differentiation of diverse cell types including erythroid cells. 13 Several studies showed that TGFb inhibits telomerase by interfering with hTERT regulatory elements such as c-myc, SIP-1 or smad3. [14] [15] [16] Based on these findings, we hypothesized that not only TGFb could repress hTERT expression in erythroid cells, but that it could also interfere with EPO-mediated hTERT regulation. As shown in Figure 5a , incubation with TGFb (10 ng/ ml) inhibited the effect of EPO on hTERT transcription. Interestingly, treatment with TGFb had no effect on STAT5 phosphorylation, c-myc induction and DNA binding activity (data not shown). These results suggested that TGFb counteracted the stimulatory effect of EPO on hTERT without interfering with the EPO-R/JAK2/STAT5/c-myc pathway. Based on these findings, we speculated that TGFb could act directly on hTERT promoter regulatory domain through the Smad pathway. The recent demonstration that TGFb could inhibit hTERT gene hTERT regulation in human erythroid cells N Prade-Houdellier et al expression via Smad3 in rat lung fibroblasts 17 supported this hypothesis. The fact that TGFb was able to activate Smad3 in UT7 cells (Figure 5b ) argued also for this possibility. Therefore, we investigated whether Smad3 could be involved in the inhibitory effect of TGFb. To test this hypothesis, we evaluated the influence of Smad3 depletion by siRNA on hTERT gene regulation by EPO and TGFb. Smad3 depletion by siRNA (Figure 5c ) restored the stimulatory effect of EPO on hTERT transcription in UT7 cells co-treated with EPO and TGFb (Figure 5d) .
These results suggested that TGFb interfered with EPOdependent hTERT regulation via Smad3.
hTERT gene regulation in erythroid progenitors
To confirm that EPO and TGFb are regulators of hTERT not only in UT7 cells but also in primary erythroid progenitors, purified CD34 þ cells of healthy donors were incubated in serum-free medium in the presence of IL3, IL6 and SCF. At day 7, CD36 þ cells were isolated and deprived of growth factors in culture medium for 4 h, then stimulated by EPO (10 U/ml) in the presence or not of AG490 (50 mM, 16 h preincubation), PD98059 (50 mM, 1 h preincubation), wortmannin (50 nM, 30 min preincubation) or TGFb (10 ng/ml, coincubation). As shown in Figure 6 , EPO induced a 1.9-fold increase in hTERT transcript expression after 6 h treatment, this stimulatory effect being abrogated by JAK2 inhibition with AG490, but not by PI3 K inhibition (wortmannin) or MAPK inhibition (PD98059). Moreover, as in UT7 cells, the addition of TGFb in the culture medium blocked EPO-induced hTERT gene transcription. In these conditions, cell loss was below 15% (data not shown).
These results suggested that, in erythroid progenitors as in UT7 cells, EPO induced hTERT transcription through the JAK2 pathway and that the TGFb inhibitory signaling was dominant over EPO stimulatory effect.
Discussion
This study shows for the first time that, in erythroid cells, EPO stimulates hTERT transcription, whereas TGFb exerts the opposite effect. The fact that EPO stimulates hTERT gene and, in parallel, enhances cell growth raised the possibility that these two effects are coupled. However, by using genetically engineered UT7 cells (UT7-DN-hTERT), we show that EPOmediated hTERT regulation serves neither for the proliferative response to EPO nor to enhance cell survival. Moreover, using UT7-DN-hTERT cells, we also found no influence of hTERT activity on differentiation stage of UT7 cells (data not shown). In a previous study, one of us has described that the loss of telomerase activity in UT7 cells resulted in decreased cell proliferation and cell death from telomere shortening after 4 weeks. 6 Combined with our results, this observation supports the notion that, whereas hTERT is dispensable for immediate proliferative response to EPO, the enzyme is still necessary for sustained cell expansion. Applied to in vivo conditions, these findings suggest that any abnormality in EPO/hTERT module should result in deferred limitation in red blood cell production. Our study shows that the JAK2/STAT5 pathway mediates EPOinduced hTERT stimulation. This finding may have important implications. For example, it is possible that constitutive activation of JAK2, as conferred by V617F mutation, may result in hTERT stimulation, which in turn contributes to long-term erythroid progenitor cell expansion. The fact that high telomerase activity has been described in granulocytes from clonal polycythemia vera supports this hypothesis. 18 The fact that JAK2/STAT5 is an important regulator of hTERT may also have important consequences in the biology of acute leukemia cells. Indeed, previous studies have established that, in acute myeloid leukemia (AML), the JAK/STAT pathway is a major target of various oncogenic products including leukemic fusion proteins and activated tyrosine kinase receptors. It is therefore tempting to speculate that constitutive JAK2/STAT5 activation at least contributes to the high telomerase activity found in AML cells. Similar mechanisms may operate in chronic myeloid leukemia cells, which also display higher telomerase activity than healthy donors. 19 EPO stimulatory effect is mediated by c-myc through JAK2, whereas MAPK and PI3K/Akt pathways are clearly not involved. This result was unexpected since it had previously been shown that PI3K and MAPK could be involved in EPO-mediated c-myc regulation through transcription and elongation. 11 However, the latter study has been performed with murine cell lines. Moreover, STAT5 has been described to stimulate c-myc transcription in response to IL-2, 20 this result being more consistent with our work.
This study also shows that TGFb exerts a potent counteracting effect against EPO-mediated hTERT stimulation. This finding may have also important implications in some pathological situations such as cancers, inflammatory diseases or myelodysplastic syndromes, in which this cytokine is abnormally produced. Indeed, in erythroid cells, TGFb-mediated hTERT downregulation may result in telomere attrition, premature senescence and cell death such as we described for TNFa in granulocytic cells. 4 Moreover, since TGFb exerts a dominant effect on EPO, such mechanisms may represent another explanation for EPO-resistant chronic anemia.
EPO and TGFb operate through independent pathways, which converge towards the regulatory domain of hTERT promoter. This was an unexpected result. Indeed, based on previous studies, our premium hypothesis was to consider that TGFb acted by interfering with c-myc induction. 16 In contrast, we observed that TGFb did not alter c-myc induction and DNA binding. Therefore, based on the documented role of Smad3 in TGFb inhibitory effect, we propose a model in which Smad3 binding does not interfere with c-myc binding, but inhibits hTERT regulation in human erythroid cells N Prade-Houdellier et al hTERT transcriptional activity. The mechanism, which underlies this intriguing observation, remains to be elucidated.
To conclude, we propose a model in which EPO stimulates hTERT transcription in erythroid progenitors through a JAK2/ STAT5/c-myc pathway. This effect is efficiently counteracted by TGFb through Smad3, the two signaling being independent. Based on telomerase function, this result suggests a role of EPOmediated hTERT regulation in red blood production.
